Acute management of bleeding in patients on novel oral anticoagulants
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous thromboembolism (VTE) after orthopaedic surgery, treatment of acute VTE, and prevention of arterial thromboembolism in non-valvular atrial fibrillation. These agents offer advantages over VKAs, including rapid onset, shorter half-lives, fewer drug interactions, and lack of need for routine monitoring. However, there are no established agents to reverse their anticoagulant effect. We review the risk of bleeding with the novel oral anticoagulants and the limitations of conventional coagulation assays for measuring anticoagulant effect. We provide an approach to the management of patients with bleeding complications with evidence for various interventions for reversal, where available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · cited 3×
“RE-LY and ROCKET AF studies showed a similar risk of bleeding with novel agents and warfarin.(13,32) In a subgroup analysis of the”
BackgroundResultRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 2×
“C row ther 492 Downloaded from https://academic.oup.com/eurheartj/article-abstract/34/7/489/599266 by guest on 29 July 2018 ADVANCE-2, Lassen et al.88 VTE prevention orthopaedic surgery Decrease in Hb ≥ 20 g/L in 24 h Transfusion ≥ 2 units packed red blood cells Bleeding at a critical site (intracranial, intraspinal,…”
BackgroundInfluentialBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353 · cited 1×
“EINSTEIN-PE, Buller et al.(85) PE acute treatment ISTH major bleeding 15 mg twice daily for 3 weeks then 20 mg daily Enoxaparin 1 mg/ kg twice daily then VKA (INR 2–3) 3, 6, or 12 months 1.”
MethodEfficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707534 · Cited by 1,255 · cited 1×
“–67 There is concern regarding thrombogenicity in nonhaemophiliac patients.(67,68) In a meta-analysis, arterial thromboembolic events were increased in non-haemophiliac patients treated with rVIIa compared with placebo (4.”
BackgroundEikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775 · cited 2×
“C row ther 492 Downloaded from https://academic.oup.com/eurheartj/article-abstract/34/7/489/599266 by guest on 29 July 2018 ADVANCE-2, Lassen et al.88 VTE prevention orthopaedic surgery Decrease in Hb ≥ 20 g/L in 24 h Transfusion ≥ 2 units packed red blood cells Bleeding at a critical site (intracranial, intraspinal,…”
BackgroundInfluentialFox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr342 · Cited by 608 · cited 2×
“RE-LY and ROCKET AF studies showed a similar risk of bleeding with novel agents and warfarin.(13,32) In a subgroup analysis of the”
BackgroundResultAgnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337 · cited 1×
“Agnelli et al.(86) VTE acute treatment ISTH major bleeding 10 mg twice daily Enoxaparin 1 mg/ kg twice daily then VKA (INR 2–3) 12 weeks 1.”
Background
Cited by
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Metadata
- Authors
- Siegal, D. M., & Crowther, M. A.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-07
- Volume
- 34
- Issue
- 7
- Pages
- 489-498
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2153134011
- Cited by
- 166
- References
- 12
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.